Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Wednesday 01 April, 2009

Lipoxen PLC

Appointment of Joint Broker

RNS Number : 9277P
Lipoxen PLC
01 April 2009

1 April 2009

Lipoxen PLC

('Lipoxen' or the 'Company')

Appointment of Joint Broker

The Board of Lipoxen announces the appointment of Noble & Company ('Noble') as joint broker to the Company with immediate effect.

-- Ends --


Lipoxen PLC 

M. Scott Maguire

Chief Executive Officer

Tel:  +44 (0) 20 7691 3583

Noble & Company

John Llewellyn-Lloyd

Tel: +44 (0) 20 7763 2200

Sam Reynolds

Citigate Dewe Rogerson

David Dible / Mark Swallow

Tel: +44 (0) 20 7638 9571

Notes to Editors on Lipoxen:

Lipoxen PLC (AIM:LPX) is a biopharmaceutical company specializing in the development of high value differentiated biologicals, vaccines and oncology drugs based on its proprietary delivery platforms. Lipoxen's PolyXen delivery technology is designed to improve the stability, biological half-life and immunologic characteristics of therapeutic proteins naturally Lipoxen currently has two products in clinical development using PolyXen, SuliXen, a long acting insulin and ErepoXen a long-acting erythropoietin (EPO). Phase I results with these novel products have shown that they have potential to deliver important dosing advantages to product currently on the market. Both SuliXen and ErepoXen are addressing multi billion dollar markets. Further products under development include improved formulations of important biologicals such as G-CSF, and Interferon-alpha. 

Lipoxen has a second naturally-derived proprietary delivery technology, ImuXen[R] and a related liposomal technology for enhancing the efficacy and safety of various vaccines including multivalent Hepatitis B-E and pneumococcal vaccines. The Company's proprietary delivery technologies are attracting significant interest and Lipoxen is currently co-developing products with the Serum Institute of India Limited (one of the world's leading vaccine companies, India's largest biotech company and a major shareholder in Lipoxen) and has license agreements in place with Baxter International and Schering Plough . Lipoxen has received funding from the International AIDS Vaccine Initiative (IAVI) to assess the potential of its ImuXen technology to develop an improved HIV vaccine. The Company is also working in collaboration on improved vaccine formulations that could be suitable for refrigeration free distribution, which would enable vaccines to be much more widely distributed to people in the developing world.

Lipoxen was admitted to trading on the AIM Market of the London Stock Exchange in January 2006. 

Notes to Editors on Noble:

Noble is a research-led independent Anglo-Indian investment bank dedicated to mid- and small-cap companies. It provides a full range of services to companies, institutions and investment vehicles, with offices in LondonEdinburgh and Mumbai.

Noble publishes high quality fundamental research on more than 170 companies in UK and India. In investment banking, Noble acts as sponsor, takeover adviser and broker on AIM, sponsor and broker on the LSE main market and adviser on Plus.  

Noble has five operating companies in the UK, covering Investment Banking, Investment Management and Growth Capital, all of which are authorised and regulated by the Financial Services Authority. 

This information is provided by RNS
The company news service from the London Stock Exchange